Infanrix DTPa-IPV+Hib, Pulver und Suspension zur Herstellung einer Injektionssuspension

7680006190030 CH-619 Pulver

Associated product:

INFANRIX DTPa-IPV+Hib susp inj (n ser pré) 0.5 ml
Infanrix DTPa-IPV+Hib, Pulver und Suspension zur Herstellung einer Injektionssuspension
Infanrix DTPa-IPV+Hib, Pulver und Suspension zur Herstellung einer Injektionssuspension
1 / 2
google

Article details

Package size
1
Selling units
1
Measure
Fertigspritze(n)
Galenic form
Pulver
Galenic group
Lösbar zur Einnahme

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
26/06/2025
Summary of Product Characteristics
Français
26/06/2025
Summary of Product Characteristics
Italien
26/06/2025

Detailed composition

Substance Quantity Type Category
I
- Substance Wirkstoff (Principe actif)
II
10.0 UG Substance Wirkstoff (Principe actif)
12C
- Substance Wirkstoff (Principe actif)
12C
- Substance Wirkstoff (Principe actif)
II
- Substance HNIDK
I
- Substance Wirkstoff (Principe actif)
12C
25.0 UG Substance Wirkstoff (Principe actif)
I
25.0 UG Substance Wirkstoff (Principe actif)
12C
25.0 UG Substance Wirkstoff (Principe actif)
I
25.0 UG Substance Wirkstoff (Principe actif)
I
8.0 UG Substance Wirkstoff (Principe actif)
12C
8.0 UG Substance Wirkstoff (Principe actif)
12C
40.0 U Substance Wirkstoff (Principe actif)
I
40.0 U Substance Wirkstoff (Principe actif)
12C
8.0 U Substance Wirkstoff (Principe actif)
I
8.0 U Substance Wirkstoff (Principe actif)
12C
32.0 U Substance Wirkstoff (Principe actif)
I
32.0 U Substance Wirkstoff (Principe actif)
12C
10.0 UG Substance Wirkstoff (Principe actif)
I
0.5 MG Substance HBESI
12C
0.5 MG Substance HBESI
I
- Substance HNIDK
I
- Substance HNIDK
12C
- Substance HNIDK
12C
- Substance HNIDK
I
1.8 MG Substance HBESI
I
- Substance HNIDK
12C
1.8 MG Substance HBESI
I
- Substance HNIDK
12C
- Substance HNIDK
12C
- Substance HNIDK
12C
- Substance HNIDK
I
- Substance RESI
I
- Substance RESI
12C
- Substance RESI
I
- Substance RESI
I
- Substance RESI
12C
- Substance RESI
12C
- Substance RESI
12C
- Substance RESI

Reimbursement information

Public price
CHF 53.75
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 15/03/1999

Authorization holder

GlaxoSmithKline AG

6340 Baar

Authorization information

Swissmedic authorization number
619
Drug name
Infanrix DTPa-IPV+Hib, Pulver und Suspension zur Herstellung einer Injektionssuspension
Galenic form
PULSIN
ATC Code
J07CA06
Authorization status
Z
Dispensing category
B
First authorization
29/09/1998
Authorization expiration date
31/12/9999
IT Number
08.08.
Domain
Human medicine
Field of application
aktive Immunisierung gegen Diphtherie, Tetanus, Pertussis, Poliomyelitis und Haemophilus influenzae Typ b, ab dem vollendeten 2. Lebensmonat, Auffrischimpfung (4. Dosis), ab dem vollendeten 12. Lebensmonat

Package details

Description (FR)
INFANRIX DTPa-IPV+Hib susp inj (n ser pré) 0.5 ml
Description (DE)
INFANRIX DTPa-IPV+Hib Inj Susp (n Fertspr) 0.5 ml
Market launch
29/09/1998
Narcotic (BTM)
No

Application methods

IMU

Other package sizes (2)

INFANRIX DTPa-IPV+Hib susp inj ser pré 0.5 ml
None None
GTIN: 7680006190016
View
INFANRIX DTPa-IPV+Hib susp inj 10 ser pré 0.5 ml
None None
GTIN: 7680006190023
Not in V1